Table 2 Randomized placebo-controlled interventional trials with intravenous glycoprotein (GP) IIb/IIIa inhibitors

EPIC (2099)

Abciximab

High-risk patients undergoing PCI

30-day composite endpoint: death, MI, CABG,

or repeat PCI

EPILOG (2792)

Abciximab

Patients with low and high risk undergoing

30-day composite endpoint: death, MI, CABG, or

PCI

repeat PCI

EPISTENT (2399)

Abciximab

Patients undergoing elective or urgent

30-day composite endpoint: death, MI, CABG, or

coronary intervention suitable for

repeat PCI

balloon angioplasty or stenting

IMPACT II (4010)

Eptifibatide

Patients undergoing elective, urgent or

30-day composite endpoint: death, MI, unplanned

emergency coronary interventions

CABG, or repeat PCI

RESTORE (2139)

Tirofiban

Patients undergoing balloon angioplasty

30-day composite endpoint: death, MI, CABG, or

or directional atherectomy within 72 hours

repeat angioplasty and stent

of ACS

CAPTURE (1265)

Abciximab

Refractory unstable angina

Death, MI, or urgent intervention for recurrent

ischemia, within 30 days

RAPPORT (483)

Abciximab

Within 12 hours of the onset of acute MI,

All-cause mortality, non-fatal MI, fatal MI, urgent

referred for angioplasty

target vessel revascularization at 6 months

ESPRIT (2064)

Eptifibatide

Undergoing non-urgent PCI with a variety

Combined endpoint: death, MI, or urgent repeat

of stents

revascularization, and need for bail-out GP IIb/IIIa

receptor blockade at 48 hours

ADMIRAL (300)

Abciximab

Patients undergoing stenting for symptoms

Composite of death, reinfarction or urgent

of acute MI within 12 hours of enrollment

revascularization at 30 days

and ST-elevation MI

TACTICS-TIMI 18

Tirofiban

Patients with unstable angina and non-ST-

Composite of death, non-fatal myocardial

(2220)

(invasive versus

elevation MI

infarction and rehospitalization for an acute

conservative strategy)

coronary syndrome

TARGET (4812)

Tirofiban versus

Non-acute MI, PCI with 'intent to stent'

Death, MI, or urgent revascularization, at 30 days

abciximab